Rosenthal, Zachary C.
Fass, Daniel M.
Payne, N. Connor
She, Angela
Patnaik, Debasis
Hennig, Krista M.
Tesla, Rachel
Werthmann, Gordon C.
Guhl, Charlotte
Reis, Surya A.
Wang, Xiaoyu
Chen, Yueting
Placzek, Michael
Williams, Noelle S.
Hooker, Jacob
Herz, Joachim
Mazitschek, Ralph
Haggarty, Stephen J.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115, R01NS108115)
Bluefield Project to Cure FTD (225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854, 225854)
Article History
Received: 6 December 2023
Accepted: 8 April 2024
First Online: 20 April 2024
Competing interests
: S.J.H. serves on the scientific advisory board (SAB) of Proximity Therapeutics, Psy Therapeutics, Frequency Therapeutics, Souvien Therapeutics, Sensorium Therapeutics, 4 M Therapeutics, Ilios Therapeutics, and Entheos Labs, none of whom were involved in the present study. S.J.H. has also received speaking or consulting fees from Amgen, AstraZeneca, Biogen, Merck, Regenacy Pharmaceuticals, Syros Pharmaceuticals, Juvenescence Life, as well as sponsored research or gift funding from AstraZeneca, JW Pharmaceuticals, Lexicon Pharmaceuticals, Vesigen Therapeutics, Compass Pathways, Atai Life Sciences, and Stealth Biotherapeutics. The funders had no role in the design or content of this article, or the decision to submit this review for publication. J.H. is a cofounder of Reelin Therapeutics, which did not provide funding and was not involved in these studies in any way. R.M. is a SAB member and equity holder of Regenacy Pharmaceuticals, ERX Pharmaceuticals, and Frequency Therapeutics. R.M. and N.C.P. are inventors on patent applications related to the CoraFluor TR-FRET probes used in this work. An invention disclosure around novel BET bromodomain compositions and therapeutic uses has been submitted to Massachusetts General Brigham Innovation. All other authors declare no competing interests.